Strong Market Presence Olpha is a major player in the Baltic pharmaceutical sector with over 50 years of experience and a diverse portfolio of more than 60 finished dosage forms and 25 active pharmaceutical ingredients, indicating a solid foundation for expanding collaborations or product partnerships.

Diverse Certification Certified under EU GMP, US cGMP, TGA, CEP, ISO 14001, and ISO 17025, Olpha demonstrates compliance with stringent international standards, making it a reliable partner for global markets and potential for joint ventures in regulated regions.

Technological Expertise With a longstanding know-how in advanced chemical areas like adamantane, quinuclidine, and nitrofurane chemistry, Olpha offers opportunities for innovation-driven collaborations or licensing agreements to leverage its technological strengths.

Expanding Portfolio Olpha's group includes specialized enterprises in supplements and other pharmaceuticals, presenting opportunities for cross-selling, co-developing new products, or entering new therapeutic segments to diversify revenue streams.

Financial Scalability With revenue estimates between $500 million and $1 billion, Olpha possesses significant financial capacity for investment in new product development, technological upgrades, or strategic acquisitions to accelerate growth.